ArticleBMC ophthalmology2026
Short-term efficacy of aflibercept 8 mg in refractory neovascular age-related macular degeneration: a retrospective case series from Taiwan.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-World Outcomes of Switching to Aflibercept 8 mg in Previously Treated Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeAflibercept 8 mg is a newly developed option for neovascular age-related macular degeneration (nAMD) class. This study explores the short-term effectiveness of aflibercept 8 mg in patients with refractory nAMD.
methodThis retrospective case series analyzed patients with refractory nAMD who received aflibercept 8 mg at Taipei Veterans General Hospital between October 2024 and April 2025. The main outcomes assessed were changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) during the initial treatment period. Secondary outcomes included evaluation of subretinal fluid (SRF), intraretinal fluid (IRF), and alterations in pigment epithelial detachment (PED) height. Data were analyzed using nonparametric statistical methods.
resultThis study included 12 eyes with refractory nAMD, 5 with refractory polypoidal choroidal vasculopathy (PCV), and 3 with refractory pachychoroid neovasculopathy (PNV), all treated with aflibercept 8 mg. Over a 3-month follow-up, no significant improvement in BCVA was observed, while CMT showed significant reductions at all time points. PED height also significantly decreased at the 1- and 3-month visits per Wilcoxon signed-rank test. Although SRF prevalence declined, the change was not statistically significant. A dry macula was achieved in 45% of eyes. Around half or more of the eyes showed a CMT reduction > 50 μm, with proportions of 50.0%, 54.5%, and 57.1% at months 1, 2, and 3, respectively.
conclusionAflibercept 8 mg demonstrated favorable anatomical outcomes in patients with neovascular macular diseases, including nAMD, PCV, and PNV. Further studies are warranted to identify factors associated with treatment response and optimize patient selection.
trial registrationNot applicable. This study is a retrospective case series and does not report a prospective health care intervention requiring trial registration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.